Literature DB >> 1677038

Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.

A Grenader1, D P Healy.   

Abstract

Fenoldopam [6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2, 3,4,5-tetrahydro-(1H)-3-benzazepine] is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties. A component of the natriuretic response to fenoldopam may involve direct DA1 receptor-mediated effects on proximal tubule sodium reabsorption, possibly through stimulation of adenylyl cyclase. Here, we compared the effects of fenoldopam and DA in stimulating cyclic AMP (cAMP) synthesis in LLC-PK1 cells, a renal epithelial cell line that has proximal tubule-like properties and expresses a DA1 receptor linked to stimulation of adenylyl cyclase. Fenoldopam stimulated cAMP accumulation in LLC-PK1 cells in a dose-dependent manner, an effect which could be blocked by the DA1-selective antagonist Sch 23390. Although fenoldopam was more potent than DA (EC50 55.5 +/- 7.75 nM vs. 1.65 +/- 0.64 microM) in stimulating cAMP accumulation in LLC-PK1 cells, the maximum stimulation obtained by fenoldopam was only 37% of the maximum stimulation obtained by DA(Emax 13.0 +/- 2.95 pmol/mg of protein vs. 35.6 +/- 10.19 pmol/mg of protein). Simultaneous incubation of DA and fenoldopam resulted in lower cAMP levels than with DA alone. Incubation of DA with increasing concentrations of fenoldopam produced parallel rightward shifts in the DA dose-response curves. Schild analysis further indicated that fenoldopam acted as a competitive antagonist in the presence of DA, with a pA2 value of 7.38 and a slope of unity. These results indicate that fenoldopam is a partial agonist with low efficacy at DA1 receptors linked to cAMP generation in the LLC-PK1 cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677038

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  A68930 is a potent, full agonist at dopamine1 (D1) receptors in renal epithelial LLC-PK1 cells.

Authors:  A Grenader; D P Healy
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  Exercise activates vagal induction of dopamine and attenuates systemic inflammation.

Authors:  Guilherme Shimojo; Biju Joseph; Roshan Shah; Fernanda M Consolim-Colombo; Kátia De Angelis; Luis Ulloa
Journal:  Brain Behav Immun       Date:  2018-10-27       Impact factor: 7.217

3.  G protein-coupled receptor kinase 4gamma interacts with inactive Galpha(s) and Galpha13.

Authors:  Lindsay B Keever; John E Jones; Bradley T Andresen
Journal:  Biochem Biophys Res Commun       Date:  2008-01-09       Impact factor: 3.575

4.  Dopamine mediates vagal modulation of the immune system by electroacupuncture.

Authors:  Rafael Torres-Rosas; Ghassan Yehia; Geber Peña; Priya Mishra; Maria del Rocio Thompson-Bonilla; Mario Adán Moreno-Eutimio; Lourdes Andrea Arriaga-Pizano; Armando Isibasi; Luis Ulloa
Journal:  Nat Med       Date:  2014-02-23       Impact factor: 53.440

5.  Dopaminergic Control of Inflammation and Glycemia in Sepsis and Diabetes.

Authors:  Eleonora Feketeova; Zhifeng Li; Biju Joseph; Roshan Shah; Zoltan Spolarics; Luis Ulloa
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

6.  The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists.

Authors:  Huayun Deng; Ye Fang
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-08

7.  Glucose Activates Vagal Control of Hyperglycemia and Inflammation in Fasted Mice.

Authors:  Biju Joseph; Guilherme Shimojo; Zhifeng Li; Maria Del Rocio Thompson-Bonilla; Roshan Shah; Alexandre Kanashiro; Helio C Salgado; Luis Ulloa
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379

8.  A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1.

Authors:  Bernhard Ellinger; Daniel Pohlmann; Jannis Woens; Felix M Jäkel; Jeanette Reinshagen; Carol Stocking; Vladimir S Prassolov; Boris Fehse; Kristoffer Riecken
Journal:  Viruses       Date:  2020-05-25       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.